Profile of:

Uta Kiltz


Uta Kiltz is a senior rheumatologist at Rheumazentrum Ruhrgebiet and a clinical lecturer, Ruhr University Bochum, Germany. She is a clinical rheumatologist with research interests and expertise in the diagnosis and management of inflammatory rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis (SpA), and gouty arthritis. She is also a lead coordinator for publishing national recommendation for axial spondyloarthritis and gouty arthritis. She has a special interest in SpA, particularly on patient-reported outcomes (PROs) and quality instruments. Over the past years, she has actively contributed to develop and translate PROs for patients with SpA (ASAS Health Index (ASAS HI), Psoriatic Arthritis Impact of Disease (PSAID), and translation into German (Psoriatic Arthritis Quality of Life (PSAQoL), Osteoarthritis Quality of Life (OAQoL), Fibromyalgia Raid Screening Tool (FiRST)). The ASAS Health Index (ASAS HI) is a unique questionnaire since it is the first questionnaire ever which is based on the International Classification of Functioning, Disability, and Health (ICF). Recently, she coordinate the development of the ASAS quality standards for assessing the quality of care in patients with axSpA. Uta Kiltz attended medical school at Ruhr University Bochum, Germany, and trained at the university hospital in Bochum before she moved to Rheumazentrum Ruhrgebiet to complete training in rheumatology. She is a member of international committees and organizations like the Assessment of Spondyloarthritis International Society (ASAS), European League Against Rheumatism (EULAR) as well as the German Society for Rheumatology (DGRh).

Full name: Uta Kiltz

Current country: Germany

Membership level: Full

Type of membership: Member

Number of publications: 41

Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials (2023)
https://pubmed.ncbi.nlm.nih.gov/36725056/

Clinically Relevant Deficits in Performance Tests in Patients With Axial Spondyloarthritis (2023)
https://www.ncbi.nlm.nih.gov/pubmed/36521921

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update (2023)
https://www.ncbi.nlm.nih.gov/pubmed/36270658

[Nonpharmacological treatment measures, rehabilitation services and membership in patient support groups in axial spondylarthritis (The ATTENTUS axSpA study)] (2023)
https://www.ncbi.nlm.nih.gov/pubmed/37725129

[Assessments and outcome parameters for axial spondylarthritis in clinical studies and routine practice] (2023)
https://www.ncbi.nlm.nih.gov/pubmed/37249611

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2 (2023)
https://www.ncbi.nlm.nih.gov/pubmed/37191738

Work participation in patients with axial spondyloarthritis: high prevalence of negative workplace experiences and long-term work impairment (2023)
https://www.ncbi.nlm.nih.gov/pubmed/36927848

Patients’ awareness towards physical activity in the treatment of axial spondyloarthritis (2023)
https://www.ncbi.nlm.nih.gov/pubmed/37127259

Global Functioning in Axial Spondyloarthritis is Stronger Associated With Disease Activity and Function Than With Mobility and Radiographic Damage (2023)
https://www.ncbi.nlm.nih.gov/pubmed/37489291

Clinical Relevance of Axial Radiographic Damage in Axial Spondyloarthritis: Evaluation of Functional Consequences by an Objective Electronic Device (2023)
https://www.ncbi.nlm.nih.gov/pubmed/37061230

Treatment overview of axial spondyloarthritis in 2023 (2023)
https://www.ncbi.nlm.nih.gov/pubmed/37673758

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis (2022)
https://academic.oup.com/rheumatology/article-abstract/61/5/2054/6371887?redirectedFrom=fulltext&login=false

Effects of patient and disease characteristics on global functioning in patients with axial spondyloarthritis in routine care (2022)
https://www.sciencedirect.com/science/article/abs/pii/S0049017222000579

The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter? (2022)
https://www.ncbi.nlm.nih.gov/pubmed/36205588

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial (2022)
https://www.ncbi.nlm.nih.gov/pubmed/33044756

The sensitivity to change of the ASAS Health Index in an observational real-life cohort study (2022)
https://www.ncbi.nlm.nih.gov/pubmed/35914790

Instrument selection for the ASAS core outcome set for axial spondyloarthritis (2022)
https://www.ncbi.nlm.nih.gov/pubmed/35680390

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis (2022)
https://www.ncbi.nlm.nih.gov/pubmed/35763155

[Effect of multimodal rheumatologic complex treatment in patients with axial spondylarthritis : A systematic evaluation with standardized outcome parameters, such as the ASAS Health Index] (2022)
https://www.ncbi.nlm.nih.gov/pubmed/35900591

Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab (2022)
https://www.ncbi.nlm.nih.gov/pubmed/35674938

[Development of quality standards for patients with axial spondyloarthritis for use in Germany] (2022)
https://www.ncbi.nlm.nih.gov/pubmed/34379181

Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis (2022)
https://www.ncbi.nlm.nih.gov/pubmed/35428719

The influence of age on the prevalence of inflammatory and structural MRI lesions in the SIJ of patients with and without axSpA (2022)
https://www.ncbi.nlm.nih.gov/pubmed/36083015

The ASAS-OMERACT core domain set for axial spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34489113/

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study (2021)
https://pubmed.ncbi.nlm.nih.gov/33462157/

Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies (2021)
https://pubmed.ncbi.nlm.nih.gov/32669450/

Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study (2021)
https://pubmed.ncbi.nlm.nih.gov/33832974/

[Development of quality standards for patients with axial spondyloarthritis for use in Germany] (2021)
https://pubmed.ncbi.nlm.nih.gov/34379181/

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34534275/

Treat-to-target in axial spondyloarthritis – what about physical function and activity? (2021)
https://pubmed.ncbi.nlm.nih.gov/34312518/

Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey (2021)
https://pubmed.ncbi.nlm.nih.gov/34334361/

Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists’ Evaluations With Radiologists’ Findings (2021)
https://pubmed.ncbi.nlm.nih.gov/33225599/

Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33044756/

The European Portuguese version of the ASAS Health Index for Patients with Spondyloarthritis: Measurement properties (2020)
https://pubmed.ncbi.nlm.nih.gov/32572012/

[Is it possible to delegate medical services to qualified nurses specialized in rheumatology when evaluating patients with suspicion of ankylosing spondylitis?-Results of the PredAS study] (2020)
https://pubmed.ncbi.nlm.nih.gov/32696075/

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/31604704/

(Health-Related) Quality of Life as an Outcome in Studies of Axial Spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/32340709/

Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis (2020)
https://pubmed.ncbi.nlm.nih.gov/30877206/

Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI (2019)
https://pubmed.ncbi.nlm.nih.gov/31245046/

[Identification of patients with axial spondylarthritis in primary care (AWARE study)] (2019)
https://pubmed.ncbi.nlm.nih.gov/31375960/

[Epionics SPINE-use of an objective method to examine spinal mobility in patients with axial spondyloarthritis] (2002)
https://pubmed.ncbi.nlm.nih.gov/31468167/